Phosphodiesterase 4 inhibition dose dependently stabilizes microvascular barrier functions and microcirculation in a rodent model of polymicrobial sepsis

Shock

Volumn 41, Issue 6, 2014, Pages 537-545

  Flemming, Sven ^a   Schlegel, Nicolas ^a   Wunder, Christian ^a   Meir, Michael ^a   Baar, Wolfgang ^a   Wollborn, Jakob ^a   Roewer, Norbert ^a   Germer, Christoph Thomas ^a   Schick, Martin Alexander ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

CASP; cytokines; Endothelial barrier; microcirculation; phosphodiesterase inhibitor; rolipram; sepsis

Indexed keywords

FLUORESCEIN ISOTHIOCYANATE; FLUORESCEIN ISOTHIOCYANATE ALBUMIN; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; PHOSPHODIESTERASE IV; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; PHOSPHODIESTERASE IV INHIBITOR;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCENDING COLON; CONTROLLED STUDY; DRUG MEGADOSE; ENZYME INHIBITION; EXTRAVASATION; HEMODYNAMICS; INFLAMMATION; LOW DRUG DOSE; LUNG EDEMA; MALE; MICROCIRCULATION; NONHUMAN; PERITONITIS; PERMEABILITY BARRIER; RAT; SEPSIS; ANIMAL; COINFECTION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; ENDOTHELIUM; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; COINFECTION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM; HEMODYNAMICS; MALE; MICROCIRCULATION; PHOSPHODIESTERASE 4 INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; ROLIPRAM; SEPSIS;

EID: 84901588287     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0000000000000152     Document Type: Article

References (35)

1. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, et al.: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 41(2):580-637, 2012
2. Lee WL, Slutsky AS: Sepsis and endothelial permeability. N Engl J Med 7:689-691, 2010
3. Schlegel N, Waschke J: CAMP with other signaling cues converges on Rac1 to stabilize the endothelial barrier- A signaling pathway compromised in inflammation. Cell Tissue Res 355(3):587-596, 2014
4. Schick MA, Wunder C, Wollborn J, Roewer N, Waschke J, Germer CT, Schlegel N: Phosphodiesterase-4 inhibition as a therapeutic approach to treat capillary leakage in systemic inflammation. J Physiol 590(Pt 11):2693-2708, 2012
5. Lin YC, Adamson RH, Clark JF, Reed RK, Curry FR: Phosphodiesterase 4 inhibition attenuates plasma volume loss and transvascular exchange in volumeexpanded mice. J Physiol 590(Pt 2):309-322, 2012
6. Irie K, Fujii E, Ishida H, Wada K, Suganuma T, Nishikori T, Yoshioka T, Muraki T: Inhibitory effects of cyclic AMP elevating agents on lipopolysaccharide (LPS)Yinduced microvascular permeability change in mouse skin. Br J Pharmacol 133(2):237-242, 2001
7. Zantl N, Uebe A, Neumann B, Wagner H, Siewert JR, Holzmann B, Heidecke CD, Pfeffer K: Essential role of gamma interferon in survival of colon ascendens stent peritonitis, a novel murine model of abdominal sepsis. Infect Immun 66(5):2300-2309, 1998
8. Lustig MK, Bac VH, Pavlovic D, Maier S, Grundling M, Grisk O, Wendt M, Heidecke CD, Lehmann C: Colon ascendens stent peritonitisVa model of sepsis adopted to the rat: Physiological, microcirculatory and laboratory changes. Shock 28(1):59-64, 2007
9. Bekker AY, Ritter AB, Duran WN: Analysis of microvascular permeability to macromolecules by video-image digital processing. Microvasc Res 38(2): 200-216, 1989
10. Schick MA, Isbary JT, Stueber T, Brugger J, Stumpner J, Schlegel N, Roewer N, Eichelbroenner O, Wunder C: Effects of crystalloids and colloids on liver and intestine microcirculation and function in cecal ligation and puncture induced septic rodents. BMC Gastroenterol 12:179, 2012
11. Cinel I, Dellinger RP: Advances in pathogenesis and management of sepsis. Curr Opin Infect Dis 20(4):345-352, 2007
12. Lee WL, Liles WC: Endothelial activation, dysfunction and permeability during severe infections. Curr Opin Hematol 18(3):191-196, 2011
13. Goldenberg NM, Steinberg BE, Slutsky AS, Lee WL: Broken barriers: A new take on sepsis pathogenesis. Sci Transl Med 3(88):88ps25, 2011
14. Dejager L, Pinheiro I, Dejonckheere E, Libert C: Cecal ligation and puncture: The gold standard model for polymicrobial sepsis? Trends Microbiol 19(4): 198-208, 2011
15. Traeger T, Koerner P, KesslerW, Cziupka K, Diedrich S, Busemann A, Heidecke CD, Maier S: Colon ascendens stent peritonitis (CASP)Va standardized model for polymicrobial abdominal sepsis. J Vis Exp (46):e2299, 2010
16. Schick M, Isbary T, Schlegel N, Brugger J, Waschke J, Muellenbach R, Roewer N, Wunder C: The impact of crystalloid and colloid infusion on the kidney in rodent sepsis. Intensive Care Med 36(3):541-548, 2010
17. Maier S, Traeger T, Entleutner M, Westerholt A, Kleist B, Huser N, Holzmann B, Stier A, Pfeffer K, Heidecke CD: Cecal ligation and puncture versus colon ascendens stent peritonitis: Two distinct animal models for polymicrobial sepsis. Shock 21(6):505-511, 2004
18. Schlegel N, Baumer Y, Drenckhahn D, Waschke J: Lipopolysaccharide-induced endothelial barrier breakdown is cAMP dependent in vivo and in vitro. Crit Care Med 37(5):1735-1743, 2009
19. Lin YC, Samardzic H, Adamson RH, Renkin EM, Clark JF, Reed RK, Curry FR: Phosphodiesterase 4 inhibition attenuates atrial natriuretic peptide-induced vascular hyperpermeability and loss of plasma volume. J Physiol 589(Pt 2): 341-353, 2011
20. Adamson RH, Liu B, Fry GN, Rubin LL, Curry FE: Microvascular permeability and number of tight junctions are modulated by cAMP. Am J Physiol 274(6 Pt 2): H1885YH1894, 1998
21. Krause W, Kuhne G: Anti-inflammatory activity of rolipram in a rat ear edema model. Arzneimittel Forschung 44(2):163-165, 1994
22. Spindler V, Waschke J: Beta-Adrenergic stimulation contributes to maintenance of endothelial barrier functions under baseline conditions. Microcirculation 18(2):118-127, 2011
23. de Visser YP, Walther FJ, Laghmani EH, Van Wijngaarden S, Nieuwland K, Wagenaar GT: Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury. Eur Respir J 31(3):633-644, 2008
24. Houslay MD, Schafer P, Zhang KY: Keynote review: Phosphodiesterase-4 as a therapeutic target. Drug Discov Today 10(22):1503-1519, 2005
25. Bielekova B, Richert N, Howard T, Packer AN, Blevins G, Ohayon J, McFarland HF, Sturzebecher CS, Martin R: Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood-brain barrier disruption in multiple sclerosis. Mult Scler 15(10):1206-1214, 2009
26. Lehtonen LA, Antila S, Pentikainen PJ: Pharmacokinetics and pharmacodynamics of intravenous inotropic agents. Clin Pharmacokinet 43(3):187-203, 2004
27. Bangash MN, Kong ML, Pearse RM: Use of inotropes and vasopressor agents in critically ill patients. Br J Pharmacol 165(7):2015-2033, 2012
28. Holthoff JH, Wang Z, Patil NK, Gokden N, Mayeux PR: Rolipram improves renal perfusion and function during sepsis in the mouse. J Pharmacol Exp Ther 347(2):357-364, 2013
29. Goncalves de Moraes VL, Singer M, Vargaftig BB, Chignard M: Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharideinduced inflammation in mouse lung. Br J Pharmacol 123(4):631-636, 1998
30. Henrich M, Gruss M, Weigand MA: Sepsis-induced degradation of endothelial glycocalix. Sci World J 10:917-923, 2010
31. Wei Z, Yang J, Xia YF, Huang WZ, Wang ZT, Dai Y: Cardamonin protects septic mice from acute lung injury by preventing endothelial barrier dysfunction. J Biochem Mol Toxicol 26(7):282-290, 2012
32. Koga S, Morris S, Ogawa S, Liao H, Bilezikian JP, Chen G, Thompson WJ, Ashikaga T, Brett J, Stern DM, et al.: TNF modulates endothelial properties by decreasing cAMP. Am J Physiol 268(5):C1104YC1113, 1995
33. Seybold J, Thomas D, Witzenrath M, Boral S, Hocke AC, Brger A, Hatzelmann A, Tenor H, Schudt C, Krll M, et al.: Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: Role in endothelial hyperpermeability. Blood 105(9):3569-3576, 2005
34. Schlegel N, Waschke J: Impaired cAMP and Rac 1 signaling contribute to TNF-alphaYinduced endothelial barrier breakdown in microvascular endothelium. Microcirculation 16(6):521-533, 2009
35. Moss A: The angiopoietin:Tie 2 interaction: A potential target for future therapies in human vascular disease. Cytokine Growth Factor Rev 24(6): 579-592, 2013